RecruitingNCT06475898
Longitudinal Endpoint Assessment of Disease Burden in HD
Sponsor
Huntington Study Group
Enrollment
600 participants
Start Date
Jun 25, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
LEAD-HD is intended to collect and analyze self-reported health information from individuals with Huntington Disease (HD) or prodromal HD participating in a 24-month longitudinal natural history study using remote technologies.
Eligibility
Min Age: 18 Years
Inclusion Criteria9
- Be 18 years of age or older;
- Be willing and able to provide informed consent electronically;
- Self-report, when answering as a participant, that you have been diagnosed with HD by a doctor, or have undergone genetic testing and been found to carry the gene mutation responsible for HD but have not been clinically diagnosed with HD (prodromal HD);
- Have the ability to answer online questions or direct someone else to enter answers for them;
- Have the ability to ambulate independently and take care of some of your personal needs;
- Have the ability to read and understand English;
- Be willing to create a unique identifier based on personal demographic information;
- Reside in the United States or its territories. Surveys can only be completed in the US. If you move outside of the US, you will no longer be able to participate;
- Own or have access to an electronic device and secure internet connectivity
Exclusion Criteria1
- \-
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06475898
Related Trials
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
NCT0732670910 locations
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
NCT0666741445 locations
Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease
NCT075138441 location
Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease
NCT0687333412 locations
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
NCT061474141 location